Concepedia

Philipp Janser

PJ

Statistics

Publications

14

Citations

751

H-Index

14

Active since

1985

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Philipp Janser is an author at Novartis (Switzerland) specializing in pharmacology, drug discovery, and medicinal chemistry.

Publications per year

1985–2024

14

Publications

14

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Daniela Angst, F. Gessier, Philipp Janser et al. · Journal of Medicinal Chemistry · 2020 · 162 citations · Full text

, , +14

Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK

Rudolf Waelchli, Birgit Bollbuck, Christian Bruns et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 148 citations · Full text

, , +8

A Potent and Selective S1P1 Antagonist with Efficacy in Experimental Autoimmune Encephalomyelitis

Jean Quancard, Birgit Bollbuck, Philipp Janser et al. · Chemistry & Biology · 2012 · 128 citations

, , +10

Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors

Juraj Velcicky, Philipp Janser, Nina Gommermann et al. · Journal of Medicinal Chemistry · 2024 · 41 citations · Full text

, , +17

Some iridium(I) and iridium(III) complexes with the tripod-like ligand CH3C(CH2PPh2)3 (triphos) and the X-ray crystal structure of [IrCl(CO)(triphos)]

Philipp Janser, Luigi M. Venanzi, F. Bachechi · Journal of Organometallic Chemistry · 1985 · 38 citations

, , +10

1–5 of 14